by admin | Apr 24, 2024 | News
Exogenus Therapeutics is proud to announce a strategic investment led by 3xP Global. This funding of 3xP Global will significantly advance the development of Exogenus lead product, Exo-101, that derived from umbilical cord blood cells and has shown promise in multiple...
by admin | Dec 13, 2022 | News
Exogenus Therapeutics CEO, Joana Simões Correia, participated in a roundtable organized by Cell & Gene Therapy Insights and Miltenyi, as part of a discussion panel about “Diagnostic & therapeutic uses for extracellular vesicles (EVs): insights into a rapidly...
by admin | Dec 7, 2022 | News
A meeting report from the 2021 massivEVs workshop entitled “Large-scale production of extracellular vesicles: Report on the “massivEVs” ISEV workshop” is now online. The massivEVs workshop took place on October 2021 and addressed the efforts towards large scale EV...
by admin | Nov 8, 2022 | News
We are proud to be awarded at the 5th Blue Bio Value Accelerator, which included the participation of 18 selected startups from 12 countries. This international cohort focused on innovative solutions aligned with blue economy principles. Organized by Oceano Azul...
by admin | Oct 17, 2022 | News
Exogenus Therapeutics announces that its exclusively licensed patent entitled “USE OF UMBILICAL CORD BLOOD DERIVED EXOSOMES FOR TISSUE REPAIR” has been granted in China and Korea. The patent describes the use of extracellular vesicles secreted by umbilical cord blood...
